

## LAURUS LABS LTD. Q2 & H1 FY21 RESULTS CONFERENCE CALL ON FRIDAY, OCTOBER 30, 2020 AT 11:00 AM IST

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Friday, October 30, 2020 at 11:00 am IST.

The conference call will be initiated with a brief management discussion on the Q2 & H1 FY21 results, followed by an interactive Question & Answer session. The call will be hosted by Kotak Institutional Equities.

**Details of the conference call are as follows:**

**For Diamond pass please Copy this URL in your browser:**

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=0632468&linkSecurityString=1ca119acc>

|                           |                                                |
|---------------------------|------------------------------------------------|
| <b>Timing</b>             | 11:00 am IST on Friday, October 30, 2020       |
| <b>Conference dial-in</b> |                                                |
| Primary number            | +91 22 6280 1214                               |
| Secondary Number          | +91 7045671221 <i>Available all over India</i> |
| Singapore                 | +6531575746                                    |
| Hong Kong                 | +85230186877                                   |
| USA                       | +13233868721                                   |
| UK                        | +442034785524                                  |

**- ENDS -**

**For LAURUS LABS LIMITED**

  
**V. V. RAVI KUMAR**  
**EXECUTIVE DIRECTOR & CFO**

**OCTOBER 26, 2020**

**About Laurus Labs Ltd.**

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. **Corporate Identification No: L24239AP2005PLC047518**

**For further information, please contact**

---

**Monish Shah**


**Laurus Labs Limited**

**Tel:** +91 40 6659 4366

**Email:** monish.shah@lauruslabs.com

---

For LAURUS LABS LIMITED

  
V. V. RAVI KUMAR  
EXECUTIVE DIRECTOR & CFO